Shigeru Yamaguchi

Shigeru Yamaguchi


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Ultrasonics Sonochemistry
Verified
Journal Article
Closed access
SYShigeru Yamaguchi
Shigeru Yamaguchi
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
TNTakuhito Narita
Takuhito Narita
KKKoki Kanehira
Koki Kanehira
SSShuji Sonezaki
Shuji Sonezaki
KHKiyohiro Houkin
Kiyohiro Houkin

4 February 2012 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
KHKenji Hirata
Kenji Hirata
STShunsuke Terasaka
Shunsuke Terasaka
TSTohru Shiga
Tohru Shiga
NHNaoya Hattori
Naoya Hattori
KMKeiichi Magota
Keiichi Magota
NTNagara Tamaki
Nagara Tamaki

7 July 2010 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
SYShigeru Yamaguchi
Shigeru Yamaguchi
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
TNTakuhito Narita
Takuhito Narita
KKKoki Kanehira
Koki Kanehira
SSShuji Sonezaki
Shuji Sonezaki
YIYoshinobu Iwasaki
Yoshinobu Iwasaki

1 February 2019 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
MYMichiharu Yoshida
Michiharu Yoshida
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
STShunsuke Terasaka
Shunsuke Terasaka
SEShogo Endo
Shogo Endo
SYShigeru Yamaguchi
Shigeru Yamaguchi
KHKiyohiro Houkin
Kiyohiro Houkin

23 November 2020 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
HAHideyuki Arita
Hideyuki Arita
YMYuko Matsushita
Yuko Matsushita
RMRyunosuke Machida
Ryunosuke Machida
KYKai Yamasaki
Kai Yamasaki
NHNobuhiro Hata
Nobuhiro Hata
KIKoichi Ichimura
Koichi Ichimura
TERT promoter mutations are commonly associated with 1p/19q codeletion in IDH-mutated gliomas. However, whether these mutations have an impact on patient survival independent of 1p/19q codeletion is unknown. In this study, we investigated the impact of TERT promoter mutations on survival in IDH-mutated glioma cases. Detailed clinical information and molecular status data were collected for a cohort of 560 adult patients with IDH-mutated gliomas. Among these patients, 279 had both TERT promoter mutation and 1p/19q codeletion, while 30 had either TERT promoter mutation (n = 24) or 1p/19q codeletion (n = 6) alone. A univariable Cox proportional hazard analysis for survival using clinical and genetic factors indicated that a Karnofsky performance status score (KPS) of 90 or 100, WHO grade II or III, TERT promoter mutation, 1p/19q codeletion, radiation therapy, and extent of resection (90–100%) were associated with favorable prognosis (p < 0.05). A multivariable Cox regression model revealed that TERT promoter mutation had a significantly favorable prognostic impact (hazard ratio = 0.421, p = 0.049), while 1p/19q codeletion did not have a significant impact (hazard ratio = 0.648, p = 0.349). Analyses incorporating patient clinical and genetic information were further conducted to identify subgroups showing the favorable prognostic impact of TERT promoter mutation. Among the grade II-III glioma patients with a KPS score of 90 or 100, those with IDH-TERT co-mutation and intact 1p/19q (n = 17) showed significantly longer survival than those with IDH mutation, wild-type TERT, and intact 1p/19q (n = 185) (5-year overall survival, 94% and 77%, respectively; p = 0.032). Our results demonstrate that TERT promoter mutation predicts favorable prognosis independent of 1p/19q codeletion in IDH-mutated gliomas. Combined with its adverse effect on survival among IDH-wild glioma cases, the bivalent prognostic impact of TERT promoter mutation may help further refine the molecular diagnosis and prognostication of diffuse gliomas.

1 October 2008 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
YSYutaka Sawamura
Yutaka Sawamura
KKKyousuke Kamada
Kyousuke Kamada
YKYuuta Kamoshima
Yuuta Kamoshima
SYShigeru Yamaguchi
Shigeru Yamaguchi
TTToshihiro Tajima
Toshihiro Tajima
TFTakamitsu Fujimaki
Takamitsu Fujimaki
Optic pathway/hypothalamic pilocytic astrocytomas in children are usually treated with chemotherapy following a surgical biopsy. In this report, we r